XML 89 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue from Contracts with Customers (Tables)
 3 Months Ended
Mar. 31, 2020
Revenue from Contracts with Customers [Abstract]  
Disaggregation of Revenue [Table Text Block]
disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three months ended March 31, 2020 and 2019:
 
 
Three Months Ended
 
Three Months Ended
 
 
March 31, 2020
 
March 31, 2019
(in thousands)
 
Medical Devices
 
Pharmaceutical (1)
 
Medical Devices
 
Pharmaceutical (1)
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
2,718

 
$
4,186

 
$
2,084

 
$
12,138

Europe
 
923

 
5,759

 
1,017

 
5,582

Asia
 
1,120

 
5,086

 
2,269

 
2,241

Other
 
136

 
—

 
119

 
—

Total revenue from contracts with customers (2)
 
$
4,897

 
$
15,031

 
$
5,489

 
$
19,961

________________
(1)
The revenue from the Company’s Pharmaceutical segment for the three months ended March 31, 2020 and 2019 is included in (Loss) income from discontinued operations. For additional information, see Note 2, Discontinued Operations Classified as Assets held for sale.    
(2) 
The table above does not include lease revenue from the Company’s Medical Devices segment for the three months ended March 31, 2020 and 2019, of $1.1 million and $1.2 million, respectively.
Contract with Customer, Asset and Liability [Table Text Block]
The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)
 
March 31, 2020
 
December 31, 2019
 
 
 
 
 
Receivables, net
 
$
7,865

 
$
10,377

Contract assets
 
$
4,830

 
$
3,512

Contract liabilities
 
$
5,680

 
$
4,024


Receivables, Net—Receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintains an allowance for credit losses to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables, collateral to the extent applicable and reflects the possible impact of current conditions and reasonable forecasts not already reflected in historical loss information. Receivables, net for our Pharmaceutical segment are classified as a current asset and included in Assets held for sale. See Note 2, Discontinued Operations Classified as Assets Held for Sale, for additional information.

Contract Assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company’s contract assets are only attributable to the Pharmaceutical segment, and as such classifies contract assets in Assets held for sale in the Company’s Condensed Consolidated Balance Sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract assets at December 31, 2019
 
$
—

 
$
3,512

 
$
3,512

Contract assets recognized
 
—

 
(2,341
)
 
(2,341
)
Payments received
 
—

 
3,659

 
3,659

Contract assets at March 31, 2020
 
$
—

 
$
4,830

 
$
4,830


Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies Medical Devices deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets. The Pharmaceutical deferred revenue is classified as a current liability and included in Liabilities held for sale.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract liabilities at December 31, 2019
 
$
1,075

 
$
2,949

 
$
4,024

Contract liabilities recognized
 
320

 
2,432

 
2,752

Amounts recognized into revenue
 
(377
)
 
(719
)
 
(1,096
)
Contract liabilities at March 31, 2020
 
$
1,018

 
$
4,662

 
$
5,680
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.
 
 
Nine Months Ended
 
 
 
 
(in thousands)
 
December 31, 2020
 
Thereafter
 
Total
 
 
 
 
 
 
 
Medical device sales
 
$
4,416

 
$
6,542

 
$
10,958

Pharmaceutical product sales
 
$
287

 
$
3,443

 
$
3,730